+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07130032

Study of Anti-PD-1PD-L1 Antibodies Combined With Bevacizumab and Low-Dose Cyclophosphamide for Metastatic Non-Small Cell Lung Cancer and Cutaneous Melanoma Previously Treated with Immune Checkpoint Blockade

Led by EuroCityClinic LLC · Updated on 2025-08-19

90

Participants Needed

1

Research Sites

119 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of combining anti-PD-1PD-L1 antibodies with bevacizumab and metronomic cyclophosphamide in people with metastatic non-small cell lung cancer NSCLC and cutaneous melanoma who have previously been treated with immune checkpoint blockade ICB. This study aims to improve progression-free survival, overall survival, and increase the rates of objective responses and disease control by targeting multiple resistance pathways in these cancers. Participants will receive a combination treatment called the reICB regimen, which includes anti-PD-1PD-L1 antibodies, daily low-dose oral cyclophosphamide, and bevacizumab every three weeks. Those with metastatic NSCLC or cutaneous melanoma will continue this treatment until their disease progresses or they experience unacceptable side effects. Different dosing schedules are used depending on the antibody chosen, with treatments administered intravenously at set intervals. During the study, participants will be monitored for tumor response using immune-related response criteria, along with assessments of progression-free and overall survival up to 24 months. Researchers will also track disease control rates, duration of response, and any treatment-related adverse events for up to approximately 38 months. Regular evaluations will include clinical exams, laboratory tests, and safety monitoring to assess the treatment effects and participant well-being throughout the trial.

CONDITIONS

Brief Title

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Research Team

S

Sergey V. Orlov, Professor

A

Aram A. Musaelyan, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here